Table 2.

Laboratory tests before and after tocilizumab

Normal rangeBefore tocilizumabAfter tocilizumab
D1D3D5
White cell count, ×109/L3.5–9.56.30 ± 2.77 (4/20, 20.0%)8.05 ± 4.39 (8/18, 44.4%)6.02 ± 3.05 (9/21, 42.9%)5.25 ± 2.11 (2/19, 10.5%)
Lymphocyte percentage, %20–5015.52 ± 8.89 (17/20, 85.0%)11.78 ± 11.36 (16/18, 88.9%)16.93 ± 13.59 (14/21, 66.7%)22.62 ± 13.48 (9/19, 47.4%)
CRP, mg/L0–575.06 ± 66.80 (20/20, 100%)38.13 ± 54.21 (17/18, 94.4%)10.61 ± 13.79 (10/20, 50.0%)2.72 ± 3.60 (3/19, 15.8%)
Procalcitonin, ng/mL0–0.50.33 ± 0.78 (2/20, 10.0%)0.21 ± 0.35 (2/16, 12.5%)0.09 ± 0.13 (1/19, 5.3%)0.12 ± 0.15 (1/18,5.6%)
IL-6, pg/mL0–7153.44 ± 296.63 (18/18, 100%)129.18 ± 131.79 (13/13, 100%)300.98 ± 341.90 (17/17, 100%)274.90 ± 414.08 (12/12, 100%)
  • Data are means ± SD (abnormal no./total no., %). D, day after tocilizumab.